Occident Group

Lymphatica Medtech SA is a Swiss company that specializes in the design and manufacture of medical devices aimed at treating lymphatic diseases, particularly lymphedema. Founded in 2017 and based in Lausanne, the company has developed innovative solutions such as the LymphoDrain system, which includes an active implantable lymphatic bypass that integrates a magnetically controlled micropump and subcutaneous catheters. This technology is designed to re-establish lymphatic circulation by internally draining lymphatic fluid from multiple points in the affected limb, providing a minimally invasive remedy for patients suffering from lymphedema. Lymphatica Medtech's commitment to advancing treatment options in this field reflects its focus on improving patient outcomes through cutting-edge medical technology.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Altavo is a medical device startup focused on developing innovative solutions for individuals who have lost their ability to speak due to surgery or disease. The company leverages advanced machine learning and cutting-edge sensor technology to create custom, natural-sounding artificial voices. By employing speech recognition and synthesis techniques, Altavo aims to restore the ability to communicate, significantly enhancing the quality of life for those with speech disorders. Through its innovative approach, Altavo addresses a critical need in the healthcare sector, providing voiceless individuals with a means to express themselves effectively.

Chipmetrics is a specialized business focused on the development of test structures, chips, and wafer concepts for advanced materials and microelectronics manufacturing. The company's core expertise lies in characterizing thin film conformality, with a mission to accelerate applications of conformal 3D thin films. Its primary product line, PillarHall test chips, enables clients to swiftly obtain accurate data on thin film conformality, facilitating comparisons between different 3D thin film processes and reactors.

ReCatalyst is a company focused on the development and commercialization of advanced catalysts for hydrogen fuel cells. It specializes in platinum-alloy catalysts, offering patented nano-catalyst technology that enhances stability and reduces the amount of platinum required in fuel cell systems. This innovation enables greater scalability of high-power proton exchange membrane fuel cells while optimizing the use of platinum group metals. By improving the efficiency and sustainability of fuel cell technology, ReCatalyst aims to contribute significantly to the growing hydrogen energy sector.

EBAMed SA is a Swiss startup based in Geneva that specializes in developing innovative medical devices for the non-invasive treatment of heart arrhythmias. Founded in 2018, the company focuses on creating an ultrasound-based device that utilizes proton therapy to monitor heart motion and synchronize therapeutic beams in real time. This technology allows for the precise delivery of radiation treatment to targeted heart tissues, thereby expanding treatment options for existing proton therapy centers and enabling them to treat heart patients effectively. By providing a non-invasive approach to cardiac care, EBAMed aims to improve patient outcomes and streamline treatment processes in outpatient settings.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

iThera Medical is a biotechnology company founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, specializing in photonic molecular imaging technology. The company focuses on the development of its proprietary multispectral optoacoustic tomography (MSOT) technology, which offers real-time visualization of anatomical, functional, and molecular information in living tissues. This innovative imaging solution enhances the ability of healthcare professionals to detect tumors and inflammatory diseases non-invasively, thereby facilitating preclinical and clinical trials. By advancing its technology, iThera Medical aims to improve diagnostic capabilities and patient outcomes in the medical field.

Resistell AG is a Swiss company founded in 2018, based in Muttenz, specializing in the development and marketing of innovative diagnostic devices for antibiotic susceptibility testing. The company's platform employs advanced nanomotion technology to detect the movement of living bacterial cells, allowing for the rapid identification of bacterial resistance to antibiotics. This method serves as an alternative to traditional culture-based antibiograms, enabling healthcare providers to administer appropriate antibiotics in a timely manner, ultimately improving patient outcomes.

core sensing breathes new life into machines. The innovative coreIN product line integrates innovative IoT sensor technology into standard mechanical components. This patented technology enables easy implementation and real-time data collection - without complex redesigns. Smart components, smart insights coreIN goes far beyond simple component replacement. The smart components provide valuable real-time data and intelligent analytics that optimize functionality. The robust IoT sensor platform coreNET ensures a seamless connection from the sensor to the cloud. This enables breakthrough products and services with high added value. The patented coreIN technology measures loads directly at the source of potential failures, enabling comprehensive machine insight. Smart sensors with advanced algorithms and AI capabilities accurately analyze machine condition and performance. Successful partnerships for breakthrough innovation Together with our partners, we develop intelligent series products that set new standards. Our customers include well-known companies in various industries, including Roll Forming Machines, Conveyor Belts & Trucks.

Avelo is a manufacturer of breath aerosol diagnostic equipment focused on providing rapid testing solutions for infectious diseases. The company has developed a non-invasive sample-to-answer breath test that reliably detects multiple lower respiratory tract infections within minutes. This process involves three simple steps, allowing healthcare providers to make timely and informed decisions regarding antibiotic or antiviral treatments. Avelo's innovative approach aims to enhance the speed and accuracy of diagnoses in primary care settings, ultimately contributing to improved patient outcomes and the potential to save lives through early intervention.

Invasight is a clinical biotech company based in Zurich, Switzerland, founded in 2019. The company specializes in advancing cell invasion research with the aim of accelerating the development of targeted therapies for invasive cancers. By focusing on the proteins involved in cancer cell invasion, Invasight aims to create therapies that minimize the side effects typically associated with conventional cancer treatments. This innovative approach seeks to provide cancer patients with effective and safe treatment options tailored to their specific needs.

Code Intelligence GmbH, founded in 2017 and based in Bonn, Germany, specializes in developing advanced security software for application developers. The company offers an automated application security testing platform that employs coverage-based fuzzing and symbolic code execution to help identify and rectify security vulnerabilities in code. By automating various software attack simulations, Code Intelligence enables organizations to implement continuous security testing, significantly reducing the level of expert knowledge required for setup. Their solutions are designed to enhance the reliability and security of software, serving a diverse clientele that includes major global corporations such as Bosch, Deutsche Börse Group, and Deutsche Telekom.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

Hemotune AG is a medical device company based in Zürich, Switzerland, founded in 2016. The company specializes in developing a therapeutic blood purification platform that utilizes magnetic blood purification technology to address infections and other health ailments. Hemotune's innovative approach involves the use of magnetic beads, which facilitate the selective and efficient removal of large biomolecules from the bloodstream. This technology focuses on the immunological aspects of conditions like sepsis, allowing for targeted treatment that addresses multiple disease pathways. By enhancing the purification of blood in acute care settings, Hemotune aims to improve patient outcomes for those suffering from blood-related diseases.

Tubulis GmbH, founded in 2019 and based in Munich, Germany, specializes in the research, design, and development of protein-drug conjugates, particularly focusing on antibody-drug conjugates (ADCs). The company aims to create transformative chemotherapeutic medications that are tailored to combat cancer and chronic diseases. By integrating proprietary technologies with disease-specific biology, Tubulis develops unique protein-drug combinations that enable clinicians to treat patients while minimizing the adverse effects typically associated with traditional chemotherapy. Through its innovative approach, Tubulis seeks to improve therapeutic outcomes and enhance the safety of cancer treatments.

Code Intelligence GmbH, founded in 2017 and based in Bonn, Germany, specializes in developing advanced security software for application developers. The company offers an automated application security testing platform that employs coverage-based fuzzing and symbolic code execution to help identify and rectify security vulnerabilities in code. By automating various software attack simulations, Code Intelligence enables organizations to implement continuous security testing, significantly reducing the level of expert knowledge required for setup. Their solutions are designed to enhance the reliability and security of software, serving a diverse clientele that includes major global corporations such as Bosch, Deutsche Börse Group, and Deutsche Telekom.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

Resistell AG is a Swiss company founded in 2018, based in Muttenz, specializing in the development and marketing of innovative diagnostic devices for antibiotic susceptibility testing. The company's platform employs advanced nanomotion technology to detect the movement of living bacterial cells, allowing for the rapid identification of bacterial resistance to antibiotics. This method serves as an alternative to traditional culture-based antibiograms, enabling healthcare providers to administer appropriate antibiotics in a timely manner, ultimately improving patient outcomes.

GNA Biosolutions is a molecular technology company located in Martinsried, Germany, specializing in the development of innovative molecular diagnostic devices for detecting and analyzing DNA. The company utilizes its proprietary Pulse Controlled Amplification technology to enhance nucleic acid amplification and detection, featuring rapid heating and cooling rates. This advancement allows laboratories to efficiently diagnose and amplify human pathogens and DNA, simplifying the molecular testing process. GNA Biosolutions aims to make the power of molecular testing accessible to a broader audience, facilitating both laboratory and on-site applications, as well as Point of Care solutions.

Resistell AG is a Swiss company founded in 2018, based in Muttenz, specializing in the development and marketing of innovative diagnostic devices for antibiotic susceptibility testing. The company's platform employs advanced nanomotion technology to detect the movement of living bacterial cells, allowing for the rapid identification of bacterial resistance to antibiotics. This method serves as an alternative to traditional culture-based antibiograms, enabling healthcare providers to administer appropriate antibiotics in a timely manner, ultimately improving patient outcomes.

iThera Medical is a biotechnology company founded in 2010 as a spin-off from the Helmholtz Zentrum Muenchen, specializing in photonic molecular imaging technology. The company focuses on the development of its proprietary multispectral optoacoustic tomography (MSOT) technology, which offers real-time visualization of anatomical, functional, and molecular information in living tissues. This innovative imaging solution enhances the ability of healthcare professionals to detect tumors and inflammatory diseases non-invasively, thereby facilitating preclinical and clinical trials. By advancing its technology, iThera Medical aims to improve diagnostic capabilities and patient outcomes in the medical field.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

Adivo GmbH is a veterinary biotechnology company based in Planegg, Germany, that focuses on developing species-specific therapeutic antibodies for companion animals, particularly dogs. The company aims to address serious diseases in pets while also exploring the potential for therapies applicable to other species. Adivo utilizes a new, fully synthetic, dog-specific drug library to isolate antibodies with optimal properties through phage display technology. The team at Adivo brings extensive experience from the development of human therapeutic antibodies, leveraging this expertise to innovate within the field of veterinary medicine. As a spin-off of MorphoSys AG, Adivo is positioned to advance therapeutic options for pets, contributing to improved health outcomes in companion animals.

InSphero AG, founded in 2009 and headquartered in Schlieren, Switzerland, specializes in developing organotypic 3D microtissues and microtissue-based assays for biochemical compound screening and predictive drug testing. The company offers a range of 3D cell culture platforms and methods that enable the reproducible production of assay-ready 3D InSight Microtissues derived from various organs such as liver, pancreas, tumor, heart, brain, and skin. These microtissues are used in applications including toxicity testing, drug metabolism, pharmacokinetics, cancer research, stem cell research, and disease modeling. InSphero provides services like hepatotoxicity testing, oncology service packs, and embryonic stem cell tests, along with custom development services for microtissue creation and analysis. The company's technology aims to deliver biologically relevant insights for in vitro testing, helping biotechnological industries make informed preclinical decisions while reducing animal use in testing.

advanceCOR GmbH is a drug development company based in Munich, Germany, specializing in the research, development, and commercialization of therapeutics and diagnostics for heart and vascular diseases. Founded in 2000, the company focuses on personalized treatment solutions and offers a range of innovative products, including Revacept, a human Fc fusion protein designed to prevent platelet activation at sites of vascular injury. Additionally, advanceCOR develops COR-2, a recombinant protein that inhibits cholesterol uptake and foam cell generation, as well as COR-3, which targets atherosclerotic plaques and facilitates accelerated healing by binding to circulating progenitor cells. The company's portfolio also includes therapies for acute arterial thrombosis and thromboembolic diseases, such as myocardial infarction and stroke, as well as various monoclonal antibodies and fusion proteins aimed at enhancing treatment outcomes for patients with cardiovascular conditions.

Implandata Ophthalmic Products GmbH is a medical device company based in Hanover, Germany, that specializes in innovative solutions for glaucoma management and treatment. Founded in 2010, the company focuses on advancing care for glaucoma patients by developing disruptive technologies. Its flagship product, Eyemate, is an implantable micro sensor designed for the continuous telemetric measurement of intraocular pressure. This biocompatible device can be permanently implanted in the patient's eye without affecting vision or overall well-being, allowing for improved monitoring and management of glaucoma. Through this technology, Implandata aims to enhance the quality of care for patients, families, and caregivers, addressing an important and underserved area in glaucoma therapy.

Numbrs, headquartered in Zurich, Switzerland, is a customer-focused financial services company. It offers a mobile banking platform that allows users to manage their existing bank accounts and personal finances, and purchase financial products from various providers at competitive prices. Numbrs, with over 100 employees, does not operate as a bank itself.

Lunaphore is a biotechnology company that specializes in advanced tumor analysis through its innovative microfluidic chip technology. This platform enables the rapid extraction of spatial proteomic and transcriptome data from tumors and other tissues, transforming standard assays into multiplex spatial biology applications with a user-friendly interface. Lunaphore's solutions support researchers in fields such as immunology, immuno-oncology, and neurology, facilitating the identification of clinically relevant biomarker signatures. By streamlining the cancer diagnostic process, Lunaphore enhances the efficiency and precision of laboratory and hospital assays, ultimately contributing to improved patient outcomes and advancing therapeutic development.

Versantis AG is a Swiss pharmaceutical company focused on developing innovative medicines and diagnostics for liver diseases. Founded in 2015 and based in Zurich, Versantis aims to address significant unmet medical needs for patients globally. Its lead candidate, VS-01, is currently in preclinical development and has the potential to be the first treatment for acute liver disease while simultaneously supporting multiple failing organs. VS-01 has received Orphan Drug Designation for its application in acute liver failure. The company also has additional treatments in its pipeline, including VS-02 and VS-03, which target chronic liver diseases and drug intoxications, respectively. These developments represent substantial market opportunities and underscore Versantis' commitment to improving patient outcomes for millions affected by liver conditions and related disorders.

Numbrs, headquartered in Zurich, Switzerland, is a customer-focused financial services company. It offers a mobile banking platform that allows users to manage their existing bank accounts and personal finances, and purchase financial products from various providers at competitive prices. Numbrs, with over 100 employees, does not operate as a bank itself.

Cunesoft GmbH is a provider of cloud-based regulatory compliance software solutions tailored for the life sciences industry. Founded in 2013 and headquartered in Munich, Germany, with additional offices in Princeton, New Jersey, and Bengaluru, India, Cunesoft offers a range of Software as a Service (SaaS) products. These include cune-IDMP for regulatory master data management, cune-eCTD for electronic submission management, and cune-Track for regulatory task management. Other solutions include cune-RDMS for document navigation and tagging, cune-SOP for standard operating procedures, and cune-Portal for document sharing. Cunesoft also provides outsourcing services for regulatory procedures and submission documentation. The company is recognized for its reliability, security, and commitment to continuous innovation, serving both small and medium enterprises as well as divisions of large pharmaceutical companies globally.

iMusician Digital AG is a Swiss-based online platform founded in 2007, dedicated to empowering musicians in managing, selling, and monetizing their music. Located in Zurich, the company offers a comprehensive suite of tools that enables artists to distribute their music across major streaming services and sales platforms. iMusician focuses on simplifying the process for musicians by providing real-time sales tracking and copyright management, allowing them to concentrate on their creative work. With a small, passionate international team, iMusician Digital strives to support artists in navigating the complexities of the music industry and maximizing their revenue potential.

InSphero AG, founded in 2009 and headquartered in Schlieren, Switzerland, specializes in developing organotypic 3D microtissues and microtissue-based assays for biochemical compound screening and predictive drug testing. The company offers a range of 3D cell culture platforms and methods that enable the reproducible production of assay-ready 3D InSight Microtissues derived from various organs such as liver, pancreas, tumor, heart, brain, and skin. These microtissues are used in applications including toxicity testing, drug metabolism, pharmacokinetics, cancer research, stem cell research, and disease modeling. InSphero provides services like hepatotoxicity testing, oncology service packs, and embryonic stem cell tests, along with custom development services for microtissue creation and analysis. The company's technology aims to deliver biologically relevant insights for in vitro testing, helping biotechnological industries make informed preclinical decisions while reducing animal use in testing.

iMusician Digital AG is a Swiss-based online platform founded in 2007, dedicated to empowering musicians in managing, selling, and monetizing their music. Located in Zurich, the company offers a comprehensive suite of tools that enables artists to distribute their music across major streaming services and sales platforms. iMusician focuses on simplifying the process for musicians by providing real-time sales tracking and copyright management, allowing them to concentrate on their creative work. With a small, passionate international team, iMusician Digital strives to support artists in navigating the complexities of the music industry and maximizing their revenue potential.